Showing results (31-40 of 15,777) with videos related to
Sort By:
Pageof 1,578
Medical Oncology (Northwood, London, England)|April 28, 2022
Unique combinations of epigenetic modifiers synergistically impair the viability of the U87 glioblastoma cell line while exhibiting minor or moderate effects on normal stem cell growthArshak R Alexanian, Avonlea BrannonJournal of Tissue Engineering and Regenerative Medicine|June 8, 2012
The neural plasticity of early-passage human bone marrow-derived mesenchymal stem cells and their modulation with chromatin-modifying agentsZhiying Zhang, Arshak R AlexanianJournal of Cellular and Molecular Medicine|June 12, 2012
Dopaminergic-like cells from epigenetically reprogrammed mesenchymal stem cellsZhiying Zhang, Arshak R AlexanianInvestigational New Drugs|January 19, 2000
Reversal of drug resistance in sarcoma-45 by the new calmodulin antagonist--trihydrochloride of [1,2,5-trimethyl-4-phenyl-4-beta-[N-(beta-ethylamino)-N-4'-methoxybe nzy l]-ethylamino] piperidine (AR-2)A R Alexanian, N S ArutyunianSeminars in Hematology|August 7, 2001
Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experienceJ Crowley, J Jacobson, R AlexanianArchives of Pathology & Laboratory Medicine|March 2, 1999
Differential diagnosis of monoclonal gammopathiesR Alexanian, D Weber, F LiuAmerican Journal of Hematology|December 1, 1995
Light-heavy chain deposition disease progressing to multiple myelomaD Daliani, D Weber, R AlexanianAmerican Journal of Clinical Oncology|June 1, 1991
Alpha-interferon combination therapy of resistant myelomaR Alexanian, B Barlogie, J GuttermanPageof 1,578